
Conference Coverage
Latest News

What Pharmacists Should Know About Transitioning Patients to Buprenorphine

mRNA-1283 Associated With Lower Risk of Medically Attended COVID-19 Than BNT162b2 in Older Veterans

Diabetes Awareness Month: Pharmacists Can Lead on Screening, Education, and MTM

Semaglutide Cuts BMI in Young Children With Obesity in STEP Young

Systematic Review Finds Higher-Valency Pneumococcal Vaccines Offer Strong Economic Value for US Adults

Shorts










Continuing Education
All News

A transplant pharmacist looks at what azacitidine plus venetoclax’s event-free survival advantage over intensive chemotherapy means for induction selection, and why it doesn’t yet replace 7+3 or CPX-351.

Early germline BRCA testing identifies patients with metastatic pancreatic adenocarcinoma who can be considered for olaparib maintenance if their disease has not progressed after at least 16 weeks of first-line platinum chemotherapy.

As respiratory season peaks, here’s what to look for when a child’s prescription comes with instructions to wait.

In every practice setting, pharmacists can meet vaccine hesitancy with evidence, effective communication, and vetted resources that move patients toward “yes.”

A new US consensus on pancreatic enzyme replacement therapy in pancreatic cancer highlights how pharmacists can counsel patients on taking enzymes with food, check response early, and address barriers to filling the prescription.

Retail pharmacists use a quick checklist to spot risky antithrombotic duplicates, dosing mistakes, OTC interactions, and adherence gaps—helping prevent stroke and bleeding.

Findings from a McMaster University brief report echo the male-biased severity long documented in influenza and SARS-CoV-2, adding to mounting evidence that biological sex shapes immune responses to viral infection.

Given subcutaneously every 3 months, cemdisiran (Livsayis) is indicated for adults with AChR antibody–positive gMG and requires REMS enrollment.

FDA Approves Venglustat, First Treatment for Neurological Symptoms of GD3
The oral glucosylceramide synthase inhibitor crosses the blood-brain barrier, addressing a neurological component of the disease that enzyme replacement therapy cannot reach.

Cannabinoids pain management may need a pharmacist’s reassessment, as an ASRA Pain Medicine case report shows.

As antibiotic resistance keeps growing, Utah’s stewardship work shows how pharmacists can turn US Antibiotic Awareness Week into year-round action.

In the phase 3 REGAL trial, galinpepimut-S reached a median overall survival of 24.0 months, compared with 14.7 months for best available treatment, in patients in second or later remission.

Technology empowers patients and optimizes medication use.

Health-system pharmacists confirm therapy matches stroke mechanism, screen for bleeding risk and drug interactions, and help patients transition to outpatient care.

Balanced exposure to clinical and nonclinical careers, timed to each pathway's application calendar and built into each curriculum's structure, can help pharmacy students choose their next step deliberately.

Peer Reviewed
Identifying and screening Medicare Part D patients who are ordered brand-name cardiovascular medications for PACE/PACENET eligibility before discharge can reduce patients’ out-of-pocket costs for these medications.

Neladalkib received accelerated approval for adults with advanced ALK-positive NSCLC after specified prior therapies, supported by durable responses in the ALKOVE-1 trial.

Adrabetadex cut the risk of death by 55%, but its boxed warning for permanent hearing loss means patients need regular hearing tests.

A once-nightly drop already used to reverse pupil dilation gains a near-vision indication.

PAHO confirmed endemic measles transmission in the US, Mexico, and Bolivia, putting pharmacists' role in vaccination and case detection in focus.

Safe storage and responsible disposal help protect patients from accidental poisoning and drug misuse while keeping medications stable and effective.

A new US DOL rule will require PBMs to disclose their compensation to large self-insured employer plans starting in 2027.

Salia Farrokh, PharmD, MBA, describes how neurocritical care pharmacists have moved from answering questions to leading research, policy, and teaching, and why health systems must fund dedicated ICU pharmacists and protected time to sustain that growth.


































